Literature DB >> 24600115

Correlation of histomorphologic prognostic markers and proliferative index with loss of heterozygosity 1p/19q and MGMT status in diffusely infiltrating gliomas.

Prabal Deb1, N S Mani2, S M Sudumbrekar3, Nitin Taneja4, Seema Patrikar5.   

Abstract

BACKGROUND: Loss of heterozygosity (LOH)1p/19q, and epigenetic silencing of O(6)-methylguanine-DNAmethyltransferase (MGMT) gene, displayed promising role as predictive and prognostic markers in brain tumours. The present study correlated both with conventional histomorphologic prognostic markers and proliferative index in diffusely infiltrating gliomas (DIG).
METHODS: Tissues from 45 patients were evaluated for LOH1p/19q using polymerase chain reaction based microsatellite analysis; and for MGMT using immunohistochemistry. Results were correlated with age, histologic type, WHO grade, and proliferation index.
RESULTS: Mean MIB-1 LI showed significant correlation with tumour grade. MGMT-staining in grade II and IV tumours were 31.1% and 16.8%, respectively, while in DA and GBM it was 88.2% and 19.0%, respectively, which were statistically significant. Sixteen cases showed LOH 1p and/or 19q of which 10 (5 oligodendroglial, 3 GBM, AA, DA) had combined LOH; while three each showed 1p (all GBM) and 19q (2 DA and GBM) loss. In the MIB-1LI ≤ 5% and >5% groups LOH 1p and/or 19q was encountered in 6 and 10 cases, respectively. A significant inverse association was noted between LOH with MGMT.
CONCLUSIONS: LOH1p/19q and MGMT shows good correlation with conventional histomorphologic and proliferation markers, and should constitute part of the optimal diagnostic workup of DIG.

Entities:  

Keywords:  Diffusely infiltrating gliomas; LOH 1p/19q; MGMT; MIB-1LI

Year:  2012        PMID: 24600115      PMCID: PMC3862471          DOI: 10.1016/j.mjafi.2012.08.030

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  31 in total

Review 1.  Variability and regulation of O6-alkylguanine-DNA alkyltransferase.

Authors:  Geoffrey P Margison; Andrew C Povey; Bernd Kaina; Mauro F Santibáñez Koref
Journal:  Carcinogenesis       Date:  2003-04       Impact factor: 4.944

Review 2.  Molecular genetic analysis of oligodendroglial tumors.

Authors:  Christian Hartmann; Wolf Mueller; Ulrike Lass; Suzanne Kamel-Reid; Andreas von Deimling
Journal:  J Neuropathol Exp Neurol       Date:  2005-01       Impact factor: 3.685

3.  Comprehensive allelotype and genetic anaysis of 466 human nervous system tumors.

Authors:  A von Deimling; R Fimmers; M C Schmidt; B Bender; F Fassbender; J Nagel; R Jahnke; P Kaskel; E M Duerr; J Koopmann; D Maintz; S Steinbeck; W Wick; M Platten; D J Müller; R Przkora; A Waha; B Blümcke; R Wellenreuther; B Meyer-Puttlitz; O Schmidt; J Mollenhauer; A Poustka; A P Stangl; D Lenartz; K von Ammon
Journal:  J Neuropathol Exp Neurol       Date:  2000-06       Impact factor: 3.685

4.  Immunohistochemical study for O6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas.

Authors:  Satoshi Nakasu; Tadateru Fukami; Kazumi Baba; Masayuki Matsuda
Journal:  J Neurooncol       Date:  2004-12       Impact factor: 4.130

5.  Loss of heterozygosity on chromosome 19 in secondary glioblastomas.

Authors:  M Nakamura; F Yang; H Fujisawa; Y Yonekawa; P Kleihues; H Ohgaki
Journal:  J Neuropathol Exp Neurol       Date:  2000-06       Impact factor: 3.685

6.  Impact of genotype and morphology on the prognosis of glioblastoma.

Authors:  Matthias C Schmidt; Sven Antweiler; Nina Urban; Wolf Mueller; A Kuklik; Birgit Meyer-Puttlitz; Otmar D Wiestler; David N Louis; Rolf Fimmers; Andreas von Deimling
Journal:  J Neuropathol Exp Neurol       Date:  2002-04       Impact factor: 3.685

7.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

8.  Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets.

Authors:  Wolf Mueller; Christian Hartmann; Annegret Hoffmann; Wolfgang Lanksch; Jürgen Kiwit; Jörg Tonn; Julian Veelken; Johannes Schramm; Michael Weller; Otmar D Wiestler; David N Louis; Andreas von Deimling
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

9.  Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials.

Authors:  Daniel J Brat; Wendy F Seiferheld; Arie Perry; Elizabeth H Hammond; Kevin J Murray; Alan R Schulsinger; Minesh P Mehta; Walter J Curran
Journal:  Neuro Oncol       Date:  2004-04       Impact factor: 12.300

10.  A comparative immunohistochemistry of O6-methylguanine-DNA methyltransferase and p53 in diffusely infiltrating astrocytomas.

Authors:  Qingguo Yuan; Kenichi Matsumoto; Yusaku Nakabeppu; Toru Iwaki
Journal:  Neuropathology       Date:  2003-09       Impact factor: 1.906

View more
  1 in total

1.  Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss.

Authors:  Xia Li; Jie Wei; Yixiong Liu; Peifeng Li; Linni Fan; Yingmei Wang; Mingyang Li; Danhui Zhao; Zhou Yu; Jing Ye; Ying Guo; Qingguo Yan; Shuangping Guo; Zhe Wang
Journal:  Sci Rep       Date:  2017-10-12       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.